Maintain adequate fluid intake to prevent dehydration-related mucosal drying
Pharmacokinetic interactions involving berberine are complex
Retatrutide : This triple agonist (GLP-1 + GIP + glucagon) produced 28.7% weight loss in Phase 3 but introduced a new safety signal: dysesthesia (abnormal skin sensations) in 4.4 to 20.9% of participants at the 12 mg dose depending on trial population
Imaging: Ultrasound Guidance Elevates Precision Ultrasound enhances safety and outcomes: Visualizing tendon architecture , paratenon , bursae , and neovessels guides injection location
For patients currently in compounded GLP-1 programs, the transition would likely involve one of several options: switching to an FDA-approved branded medication (at substantially higher cost), discussing alternative weight management approaches with a licensed provider, or exploring whether 503A patient-specific compounding applies to their individual clinical situation
No conclusions can be drawn